title: Important controversies associated with isotretinoin therapy for acne.
abstract: Isotretinoin is a remarkably effective drug for severe, recalcitrant acne vulgaris. Soon after the drug's release in the early 1980s, a number of important adverse effects were reported subsequently leading to a variety of medical and medicolegal controversies. Three of these controversies will be highlighted concerning the putative role of isotretinoin in (1) depression and suicide, (2) inflammatory bowel disease, and (3) iPledge and pregnancy prevention programs. It appears that a very small subset of patients receiving isotretinoin for acne are at risk for depression, which is very manageable provided there is adequate patient awareness of the possibility, maximum communication between the patient and physician, and cessation of therapy if clinically important depression occurs (after which the depression rapidly resolves in a week or less). Multiple controlled studies actually suggest a very favorable effect of isotretinoin on depression and anxiety common in the population requiring isotretinoin. With regard to inflammatory bowel disease, in just one study, only ulcerative colitis association with isotretinoin reached statistical significance. The actual incidence of this association is strikingly low. Finally, it is clear that even the most recent pregnancy prevention program (iPledge) is no more successful than prior programs; there will likely always be a small number of female patients becoming pregnant while receiving isotretinoin for acne vulgaris.
authors.affiliation: Department of Dermatology, Indiana University, 545 Barnhill Dr, Emerson Hall 139, Indianapolis, IN 46202, USA. swolvert@iupui.edu
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Wolverton
authors.forename: Julie C
authors.initials: JC
authors.lastname: Harper
mesh_terms: D000152:Acne Vulgaris / Q000175:diagnosis / Q000188:drug therapy*; D003866:Depressive Disorder / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced* / Q000453:epidemiology; D015474:Isotretinoin / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D011247:Pregnancy; D018570:Risk Assessment; D012720:Severity of Illness Index; D013405:Suicide / Q000706:statistics & numerical data; D016896:Treatment Outcome
chemical_list: D015474:Isotretinoin